Aurobindo Pharma's subsidiary Apitoria Pharma has received 10 observations from the USFDA for its API manufacturing facility in Telangana

Hyderabad: Aurobindo Pharma Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cephalexin Tablets USP, 250 mg and

Last week, brokerage firm UBS Securities also initiated a 'sell' call on Aurobindo Pharma, assigning it a price target of Rs 1,333, predicting a 12 percent downside.

The USFDA has issued 10 observations to Aurobindo Pharma's API manufacturing unit in Telangana after a September 2024 inspection. The procedural observations will be addressed within the stipulated time.

Telangana: Aurobindo Pharma has announced that the United States Food and Drug Administration (US FDA) has issued ten observations at the closure of the inspection at the Unit-II, an

Aurobindo Pharma receives USFDA approval for Cephalexin tablets, expected to launch in Q3FY25 with CGT designation.

The Hyderabad-based pharmaceutical manufacturing company said the observations are of procedural in nature and will be responded to within the stipulated time.